LY 3039478

Drug Profile

LY 3039478

Alternative Names: LY3039478

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 11 Jan 2017 Eli Lilly collaborates with NCI Formulary to co-develop LY 3039478 in Cancer
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Cancers (solid tumours and lymphoma) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 01 Nov 2016 Eli Lilly completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02917733)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top